Tumor budding in colorectal carcinoma assessed by cytokeratin immunostaining and budding areas: Possible involvement of c‐Met
Authors:
Open Access
- 9 October 2014
- journal article
- Published by Wiley in Cancer Science
- Vol. 105 (11) , 1487-1495
Abstract
Tumor budding/sprouting has been shown to be an independent adverse prognostic factor in T1 and T3N0 colorectal carcinomas, however, its assessment could be improved by more accurate identification of budding carcinoma cells and consideration of budding areas. Moreover, tumor budding mechanisms are yet to be defined. In this study, we evaluated the identification of budding tumor cells by either H&E staining alone or H&E with immunohistochemistry and developed a scoring system based on budding grades and areas. We examined whether the budding score correlated with clinicopathologic features and prognosis and the association between tumor budding/sprouting and c-Met protein expression and phosphorylation and MET gene copy numbers because c-Met is known to play an important role in colorectal carcinoma tumorigenesis. Cytokeratin immunohistochemistry could identify tumors with shorter disease-free survival (DFS) from the low-grade budding group assessed with H&E alone. High budding scores based on budding grade and area were more significantly correlated with DFS than scores obtained using the budding grade alone. In tumors with a high budding score, c-Met expression and phosphorylation levels and MET gene copy numbers were significantly increased at the invasive front compared with those in superficial tumor portions. This study showed for the first time that high levels of phospho-c-Met at the invasive front were significantly associated with a high budding score and shorter DFS. In conclusion, a budding score assessed by budding grades and budding-positive areas correlates highly with clinicopathologic aggressive features of colorectal carcinoma.Keywords
This publication has 32 references indexed in Scilit:
- Tumor budding in colorectal carcinoma: time to take noticeLaboratory Investigation, 2012
- Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopyHistopathology, 2012
- Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesisLung Cancer, 2012
- METExpression and Amplification in Patients with Localized Gastric CancerCancer Epidemiology, Biomarkers & Prevention, 2011
- Nuclear beta-catenin expression at the invasive front and in the vessels predicts liver metastasis in colorectal carcinoma.2008
- c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastasesCancer Letters, 2008
- Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2British Journal of Cancer, 2006
- Intensity of Tumor Budding and Its Prognostic Implications in Invasive Colon CarcinomaDiseases of the Colon & Rectum, 2005
- Tumour budding as prognostic factor in stage I/II colorectal carcinomaHistopathology, 2005
- Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibitionCytokine & Growth Factor Reviews, 2002